Nicodemo “Nico” Fiorentino responsible for all compliance in the US and contract review
(Princeton, NJ) — With over eight years of experience working for multiple life sciences companies, Nicodemo “Nico” Fiorentino now heads Guerbet’s compliance counsel to strengthen compliance activities. The creation of this new US-based position is a natural step in Guerbet’s ongoing global growth and commitment to corporate responsibility.
Nico began his career with Guerbet on March 15, 2021 and is responsible for all compliance-related matters in the United States, as well as reviewing contracts. Prior to this role, Nico worked for Sun Pharmaceutical Industries, Inc. providing compliance-related support to its specialty business, and G&M Health, LLC, a compliance consulting company for the healthcare industry. He also serves as an Associate Editor and Board Member for Rockpointe Corporation’s Policy & Medicine Compliance Update, a monthly compliance publication designed for the life sciences industry.
“Nico brings extensive health and life sciences experience to Guerbet,” noted Tom McLaughlin, Guerbet’s Vice President of North America. “He’s spent most of his career offering comprehensive compliance-related support to pharmaceutical and medical device manufacturers and I am thrilled to welcome him to our team.”
Nico will be based out of Guerbet’s Princeton, New Jersey office, not far from where he received his bachelor’s degree at Rowan University and his Juris Doctor degree at Rutgers University School of Law.
“I am drawn to Guerbet because of the value the company places in its employees to carry out its mission, which has led to Guerbet becoming one of the leading experts in medical imaging worldwide. I am excited to join Guerbet and work with a team that shares a vision for the highest level of business ethics and corporate responsibility and being a part of this organization’s long-term success,” Nico noted.
Guerbet is a leader in medical imaging worldwide, offering a comprehensive range of pharmaceutical products, medical devices, and digital and AI solutions for diagnostic and interventional imaging to improve patient diagnosis and treatment.
A pioneer in contrast media for more than 90 years, with more than 2,600 employees worldwide, Guerbet continuously innovates and devotes 9% of its sales to research and development in four centers in France, Israel, and the United States. Guerbet (GBT) is listed on Euronext Paris (segment B – mid caps) and generated €712 million in revenue in 2020. For more information about Guerbet, please visit www.guerbet.com.